USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: ALPHAMED, INC
City: Wrentham
State: MA
Zip+4: 02093
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $400,050.00 4
SBIR Phase II $754,469.00 1
STTR Phase I $548,342.00 5

Award List:

Pb-212 generator for cancer therapy

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Herbert A. Moore
Award Amount: $100,012.00
Abstract:
DESCRIPTION (provided by applicant): The long-term objective of this proposal is to develop a lead-212/bismuth-212 (Pb-212/bi-212) generator and sufficient amounts of source material that will support clinical trials and approved drug products. The use of alpha emitting radionuclides in… More

Production and use of Pb-203 for cancer therapy research

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Herbert A. Moore
Award Amount: $100,038.00
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this project is to produce large amounts of high-quality lead-203 on a routine basis, at reasonable prices to support cancer research and approved drug products. It is expected that Pb-203 will be the imaging agent for therapies using… More

Production of High Specific Activity Lutetium-177

Award Year / Program / Phase: 2005 / STTR / Phase I
Agency: HHS
Research Institution: UNIV. OF MISSOURI-COLUMBIA
Principal Investigator: Cathy S. Cutler
Award Amount: $100,000.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): A separation method will be tested and evaluated to determine the feasibility of providing no carrier added lutetium-177 (Lu-177) for use in radiotherapeutic applications. An indirect method will be used to produce Lu-177 (neutron capture followed by decay).… More

Production and use of Cu-67 in cancer therapy research

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Herbert A. Moore
Award Amount: $100,000.00
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this project is to produce large amounts of high-quality copper-67 on a routine basis, at reasonable prices to support cancer research and approved drug products. Researchers using Cu-67 have obtained promising results. Unfortunately this… More

PHOTONUCLEAR PRODUCTION OF SELECTED MEDICAL ISOTOPES SBIR 208 PHASE I

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Hebert Moore
Award Amount: $100,000.00

High-Energy Imaging in Support of Radionuclide Therapy

Award Year / Program / Phase: 2006 / STTR / Phase I
Agency: HHS
Research Institution: VANDERBILT UNIVERSITY
Principal Investigator: Aaron B. Brill
Award Amount: $109,750.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this project is to design and build cameras that can efficiently detect and image isotopes that have gamma rays with energies that are typically beyond those effectively accessible with conventional cameras. There are no nuclear medicine… More

Targeting alpha particle-emitting radionuclides to the nuclei of cancer cells

Award Year / Program / Phase: 2007 / STTR / Phase I
Agency: HHS
Research Institution: UNIVERSITY OF MISSOURI
Principal Investigator: Thomas P. Quinn
Award Amount: $115,953.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): This proposal outlines a body of research to evaluate the cytotoxicity and therapeutic efficacy of radiolabeled alpha-melanocyte stimulating hormone (a-MSH) peptide analogs that target a-particle emitting radioisotopes to the nuclei of melanoma cells. The… More

Processing Ac-227 sources for lead-212 and radium-223 required by cancer research

Award Year / Program / Phase: 2007 / STTR / Phase I
Agency: HHS
Research Institution: PACIFIC NORTHWEST NATIONAL LAB
Principal Investigator: Chuck Z. Soderquist
Award Amount: $111,300.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): NIH sponsored cancer researchers have been obtaining promising results using molecules radiolabeled with lead-212 in treatment for metastatic melanoma and disseminated colon and pancreatic cancers. Another isotope, radi um-223 is being used in clinical trials in… More

Production and use of Pb-203 for cancer therapy research

Award Year / Program / Phase: 2008 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $754,469.00
Abstract:
DESCRIPTION (provided by applicant): Promising results are being obtained from studies of molecules labeled with Lead-212 (Pb-212) as potential targeted radiotherapeutic agent against metastatic melanoma. According to the American Cancer Society approximat ely 60,000 people in the US will be… More

A Pb-212 Generator Using Resistant Substrate and Rn Cold Trapping

Award Year / Program / Phase: 2009 / STTR / Phase I
Agency: HHS
Research Institution: UNIVERSITY OF MISSOURI
Principal Investigator: Gary J. Ehrhardt
Award Amount: $111,339.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): Targeted Pb-212 therapy in preclinical animal tests has shown a cure in groups receiving the highest dose of this therapy. Scaling the dose that was most efficacious in animal studies to people would bring the human dos e required from 50 to 100 mCi. This… More